Alzheimer’s vaccine, round 2

Scientists from the Tokyo Metropolitan Institute for Neuroscience and Novartis AG have published a nonviral amyloid beta DNA vaccine against Alzheimer’s disease that they hope will not have the side effects that derailed a previous anti-amyloid beta vaccine.

In AD patients, beta amyloid peptides accumulate to form hard plaques that do not dissolve and are believed to account for the loss of neuronal function and dementia. ...